BCRX logo

BioCryst Pharmaceuticals (BCRX) Revenue

BCRX Annual Revenue

$331.41 M
+$60.59 M+22.37%

31 December 2023

BCRX Revenue Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

BCRX Quarterly Revenue

$117.08 M
+$7.75 M+7.09%

30 September 2024

BCRX Quarterly Revenue Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

BCRX TTM Revenue

$412.58 M
+$30.34 M+7.94%

30 September 2024

BCRX TTM Revenue Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

BCRX Revenue Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+22.4%+25.4%+24.5%
3 y3 years+1760.6%+185.6%+261.8%
5 y5 years+1504.7%+6496.3%+744.8%

BCRX Revenue High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+110.9%at high+148.3%at high+162.5%
5 y5-yearat high+1760.6%at high+3978.2%at high+2216.3%
alltimeall timeat high>+9999.0%at high>+9999.0%at high>+9999.0%

BioCryst Pharmaceuticals Revenue History

DateAnnualQuarterlyTTM
Sept 2024
-
$117.08 M(+7.1%)
$412.58 M(+7.9%)
June 2024
-
$109.33 M(+17.9%)
$382.24 M(+7.6%)
Mar 2024
-
$92.76 M(-0.7%)
$355.39 M(+7.2%)
Dec 2023
$331.41 M(+22.4%)
$93.40 M(+7.7%)
$331.41 M(+4.4%)
Sept 2023
-
$86.74 M(+5.2%)
$317.56 M(+3.6%)
June 2023
-
$82.49 M(+19.9%)
$306.64 M(+5.9%)
Mar 2023
-
$68.78 M(-13.5%)
$289.68 M(+7.0%)
Dec 2022
$270.83 M(+72.3%)
$79.55 M(+4.9%)
$270.83 M(+13.6%)
Sept 2022
-
$75.83 M(+15.7%)
$238.44 M(+17.1%)
June 2022
-
$65.53 M(+31.3%)
$203.61 M(+8.3%)
Mar 2022
-
$49.92 M(+5.9%)
$188.03 M(+19.6%)
Dec 2021
$157.17 M(+782.4%)
$47.16 M(+15.0%)
$157.17 M(+37.8%)
Sept 2021
-
$40.99 M(-17.9%)
$114.03 M(+44.1%)
June 2021
-
$49.96 M(+162.1%)
$79.14 M(+146.9%)
Mar 2021
-
$19.06 M(+374.6%)
$32.05 M(+79.9%)
Dec 2020
$17.81 M(-63.5%)
$4.02 M(-34.2%)
$17.81 M(-66.7%)
Sept 2020
-
$6.10 M(+112.5%)
$53.52 M(+8.8%)
June 2020
-
$2.87 M(-40.5%)
$49.19 M(+3.0%)
Mar 2020
-
$4.82 M(-87.9%)
$47.77 M(-2.2%)
Dec 2019
$48.84 M(+136.5%)
$39.73 M(+2138.0%)
$48.84 M(+312.5%)
Sept 2019
-
$1.77 M(+22.6%)
$11.84 M(+2.8%)
June 2019
-
$1.45 M(-75.4%)
$11.52 M(-49.0%)
Mar 2019
-
$5.89 M(+115.7%)
$22.56 M(+9.3%)
Dec 2018
$20.65 M(-18.0%)
$2.73 M(+87.7%)
$20.65 M(-5.3%)
Sept 2018
-
$1.45 M(-88.4%)
$21.81 M(-25.1%)
June 2018
-
$12.49 M(+214.2%)
$29.12 M(+47.6%)
Mar 2018
-
$3.98 M(+2.2%)
$19.73 M(-21.7%)
Dec 2017
$25.19 M(-4.4%)
$3.89 M(-55.6%)
$25.19 M(-16.8%)
Sept 2017
-
$8.76 M(+182.7%)
$30.28 M(+3.4%)
June 2017
-
$3.10 M(-67.2%)
$29.28 M(-5.5%)
Mar 2017
-
$9.44 M(+5.1%)
$30.97 M(+17.5%)
Dec 2016
$26.35 M(-45.4%)
$8.98 M(+15.7%)
$26.35 M(+19.9%)
Sept 2016
-
$7.76 M(+62.2%)
$21.97 M(-12.8%)
June 2016
-
$4.79 M(-0.7%)
$25.20 M(-45.5%)
Mar 2016
-
$4.82 M(+4.7%)
$46.25 M(-4.2%)
Dec 2015
$48.26 M(+254.6%)
$4.60 M(-58.1%)
$48.26 M(-1.7%)
Sept 2015
-
$10.99 M(-57.5%)
$49.10 M(+18.7%)
June 2015
-
$25.84 M(+278.6%)
$41.35 M(+143.6%)
Mar 2015
-
$6.83 M(+25.3%)
$16.98 M(+24.8%)
Dec 2014
$13.61 M(-21.5%)
$5.45 M(+68.2%)
$13.61 M(-27.3%)
Sept 2014
-
$3.24 M(+120.9%)
$18.73 M(+4.7%)
June 2014
-
$1.47 M(-57.6%)
$17.88 M(+3.7%)
Mar 2014
-
$3.46 M(-67.3%)
$17.23 M(-0.6%)
Dec 2013
$17.33 M(-34.1%)
$10.57 M(+342.3%)
$17.33 M(+59.5%)
Sept 2013
-
$2.39 M(+191.0%)
$10.87 M(-23.7%)
June 2013
-
$821.00 K(-76.9%)
$14.24 M(-19.2%)
Mar 2013
-
$3.55 M(-13.3%)
$17.63 M(-33.0%)
Dec 2012
$26.29 M(+33.9%)
$4.10 M(-28.8%)
$26.29 M(-4.1%)
Sept 2012
-
$5.76 M(+36.8%)
$27.42 M(+1.9%)
June 2012
-
$4.21 M(-65.6%)
$26.90 M(+1.8%)
Mar 2012
-
$12.22 M(+133.9%)
$26.43 M(+34.5%)
Dec 2011
$19.64 M(-68.5%)
$5.22 M(-0.5%)
$19.64 M(-36.9%)
Sept 2011
-
$5.25 M(+40.5%)
$31.11 M(-17.8%)
June 2011
-
$3.73 M(-31.3%)
$37.86 M(-9.3%)
Mar 2011
-
$5.43 M(-67.4%)
$41.74 M(-33.1%)
Dec 2010
$62.38 M(-16.4%)
$16.69 M(+39.1%)
$62.38 M(-38.0%)
Sept 2010
-
$12.00 M(+57.6%)
$100.58 M(+1.5%)
June 2010
-
$7.62 M(-70.8%)
$99.13 M(+2.9%)
Mar 2010
-
$26.07 M(-52.5%)
$96.30 M(+29.1%)
Dec 2009
$74.59 M
$54.90 M(+420.4%)
$74.59 M(+38.3%)
DateAnnualQuarterlyTTM
Sept 2009
-
$10.55 M(+120.3%)
$53.93 M(+3.2%)
June 2009
-
$4.79 M(+9.8%)
$52.28 M(+4.2%)
Mar 2009
-
$4.36 M(-87.3%)
$50.15 M(-11.3%)
Dec 2008
$56.56 M(-20.6%)
$34.24 M(+285.0%)
$56.56 M(+12.0%)
Sept 2008
-
$8.89 M(+234.5%)
$50.49 M(-18.6%)
June 2008
-
$2.66 M(-75.3%)
$62.06 M(-14.8%)
Mar 2008
-
$10.77 M(-61.8%)
$72.85 M(+2.3%)
Dec 2007
$71.24 M(+1046.8%)
$28.17 M(+37.7%)
$71.24 M(+57.8%)
Sept 2007
-
$20.46 M(+52.2%)
$45.16 M(+70.5%)
June 2007
-
$13.44 M(+46.8%)
$26.48 M(+81.4%)
Mar 2007
-
$9.16 M(+337.8%)
$14.60 M(+135.1%)
Dec 2006
$6.21 M(+3989.5%)
$2.09 M(+16.9%)
$6.21 M(+50.0%)
Sept 2006
-
$1.79 M(+14.9%)
$4.14 M(+73.8%)
June 2006
-
$1.56 M(+102.1%)
$2.38 M(+170.1%)
Mar 2006
-
$771.00 K(+3589.0%)
$881.90 K(+480.6%)
Dec 2005
$151.90 K(-54.9%)
$20.90 K(-34.7%)
$151.90 K(-50.8%)
Sept 2005
-
$32.00 K(-44.8%)
$308.90 K(-21.4%)
June 2005
-
$58.00 K(+41.5%)
$392.90 K(+4.0%)
Mar 2005
-
$41.00 K(-77.0%)
$377.90 K(+12.2%)
Dec 2004
$336.90 K(-48.4%)
$177.90 K(+53.4%)
$336.90 K(+1966.9%)
Sept 2004
-
$116.00 K(+169.8%)
$16.30 K(-86.7%)
June 2004
-
$43.00 K(-130.1%)
$122.30 K(-81.3%)
Dec 2003
$653.30 K(-94.1%)
-$142.70 K(-164.3%)
$653.30 K(-17.9%)
Sept 2003
-
$222.00 K(-16.5%)
$796.00 K(-19.3%)
June 2003
-
$266.00 K(-13.6%)
$986.00 K(+36.9%)
Mar 2003
-
$308.00 K(-25.2%)
$720.00 K(-83.5%)
Sept 2002
-
$412.00 K(-23.6%)
$4.37 M(-60.2%)
Mar 2002
-
$539.00 K(-84.2%)
$10.99 M(-1.5%)
Dec 2001
$11.16 M(+236.5%)
$3.42 M(+0.6%)
$11.16 M(+30.6%)
Sept 2001
-
$3.40 M(-6.4%)
$8.54 M(+44.7%)
June 2001
-
$3.63 M(+416.9%)
$5.90 M(+70.9%)
Mar 2001
-
$703.00 K(-12.5%)
$3.45 M(+4.2%)
Dec 2000
$3.32 M(+32.6%)
$803.60 K(+5.3%)
$3.32 M(+32.0%)
Sept 2000
-
$763.00 K(-35.6%)
$2.51 M(+43.5%)
June 2000
-
$1.19 M(+110.1%)
$1.75 M(-36.5%)
Mar 2000
-
$564.00 K(>+9900.0%)
$2.76 M(-10.9%)
Dec 1999
$2.50 M(-60.9%)
-
-
Sept 1999
-
$1000.00(-100.0%)
$3.09 M(-66.0%)
June 1999
-
$2.19 M(+338.4%)
$9.09 M(+29.9%)
Mar 1999
-
$500.00 K(+25.0%)
$7.00 M(+6.1%)
Dec 1998
$6.40 M(+540.0%)
$400.00 K(-93.3%)
$6.60 M(+6.5%)
Sept 1998
-
$6.00 M(+5900.0%)
$6.20 M(+1966.7%)
June 1998
-
$100.00 K(0.0%)
$300.00 K(-75.0%)
Mar 1998
-
$100.00 K(0.0%)
$1.20 M(+100.0%)
Dec 1997
$1.00 M(-37.5%)
-
-
Sept 1997
-
$100.00 K(-90.0%)
$600.00 K(-25.0%)
June 1997
-
$1.00 M(+900.0%)
$800.00 K(-46.7%)
Mar 1997
-
$100.00 K(-116.7%)
$1.50 M(0.0%)
Dec 1996
$1.60 M(+700.0%)
-$600.00 K(-300.0%)
$1.50 M(-31.8%)
Sept 1996
-
$300.00 K(-82.4%)
$2.20 M(+10.0%)
June 1996
-
$1.70 M(+1600.0%)
$2.00 M(+400.0%)
Mar 1996
-
$100.00 K(0.0%)
$400.00 K(-20.0%)
Dec 1995
$200.00 K(-71.4%)
$100.00 K(0.0%)
$500.00 K(-16.7%)
Sept 1995
-
$100.00 K(0.0%)
$600.00 K(-14.3%)
June 1995
-
$100.00 K(-50.0%)
$700.00 K(0.0%)
Mar 1995
-
$200.00 K(0.0%)
$700.00 K(+16.7%)
Dec 1994
$700.00 K
$200.00 K(0.0%)
$600.00 K(+50.0%)
Sept 1994
-
$200.00 K(+100.0%)
$400.00 K(+100.0%)
June 1994
-
$100.00 K(0.0%)
$200.00 K(+100.0%)
Mar 1994
-
$100.00 K
$100.00 K

FAQ

  • What is BioCryst Pharmaceuticals annual revenue?
  • What is the all time high annual revenue for BioCryst Pharmaceuticals?
  • What is BioCryst Pharmaceuticals annual revenue year-on-year change?
  • What is BioCryst Pharmaceuticals quarterly revenue?
  • What is the all time high quarterly revenue for BioCryst Pharmaceuticals?
  • What is BioCryst Pharmaceuticals quarterly revenue year-on-year change?
  • What is BioCryst Pharmaceuticals TTM revenue?
  • What is the all time high TTM revenue for BioCryst Pharmaceuticals?
  • What is BioCryst Pharmaceuticals TTM revenue year-on-year change?

What is BioCryst Pharmaceuticals annual revenue?

The current annual revenue of BCRX is $331.41 M

What is the all time high annual revenue for BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals all-time high annual revenue is $331.41 M

What is BioCryst Pharmaceuticals annual revenue year-on-year change?

Over the past year, BCRX annual revenue has changed by +$60.59 M (+22.37%)

What is BioCryst Pharmaceuticals quarterly revenue?

The current quarterly revenue of BCRX is $117.08 M

What is the all time high quarterly revenue for BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals all-time high quarterly revenue is $117.08 M

What is BioCryst Pharmaceuticals quarterly revenue year-on-year change?

Over the past year, BCRX quarterly revenue has changed by +$23.68 M (+25.36%)

What is BioCryst Pharmaceuticals TTM revenue?

The current TTM revenue of BCRX is $412.58 M

What is the all time high TTM revenue for BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals all-time high TTM revenue is $412.58 M

What is BioCryst Pharmaceuticals TTM revenue year-on-year change?

Over the past year, BCRX TTM revenue has changed by +$81.17 M (+24.49%)